A pharmacy benefits manager shall utilize the national average drug acquisition cost (NADAC) as a point of reference for the ingredient drug product component of a pharmacy’s reimbursement for drugs appearing on the national average drug acquisition cost list and shall produce a report every four months, which shall be provided to the Commissioner and published by the pharmacy benefits manager on a website available to the public for no less than 24 months, of all drugs appearing on the national average drug acquisition cost list reimbursed 10 percent and below the national average drug acquisition cost, as well as all drugs reimbursed 10 percent and above the national average drug acquisition cost. For each drug in the report, a pharmacy benefits manager shall include the month the drug was dispensed, the quantity of the drug dispensed, the amount the pharmacy was reimbursed per unit or dosage, whether the dispensing pharmacy was an affiliate, whether the drug was dispensed pursuant to a state or local government health plan, and the average national average drug acquisition cost for the month the drug was dispensed. Such report shall exclude drugs dispensed pursuant to 42 U.S.C. Section 256b.
Georgia NADAC Reports –
In compliance with WV § 33-51-12. § 33-51-12:
VerusRx reports reimbursement methodologies based on the National Average Drug Acquisition Cost (NADAC) pricing benchmark. NADAC is published and maintained by the Centers for Medicare & Medicaid Services (CMS) and reflects the national average acquisition cost for outpatient prescription drugs.
VerusRx remains committed to transparency and compliance in all states where we operate. Our West Virginia NADAC reporting ensures that stakeholders have clear visibility into our reimbursement practices while supporting fair and consistent pharmacy payments.